Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Tom points out that all patients received a year of adjuvant therapy in the experimental arms, but only about 25% of the ITT population completed all nine EV cycles, and little is known about who they were. The three-arm ad hoc analysis therefore cannot isolate the adjuvant phase's benefit or necessity.

Related Insights

The trial's active monitoring arm had a 96% overall survival rate at 3 years. This high baseline survival, due to effective subsequent treatments for relapsed patients, makes it statistically challenging to demonstrate an OS benefit for any adjuvant therapy. This highlights a growing challenge for adjuvant trial design in cancers with effective salvage options.

An expert would not offer just the adjuvant portion of the EV-Pembro regimen to a patient who went straight to surgery, even though the full perioperative (neoadjuvant + adjuvant) regimen is approved. This highlights a strict adherence to trial data, where the lack of specific evidence for a purely adjuvant application prevents off-label use.

A critical design flaw in most perioperative chemo-immunotherapy trials is the lack of a 'contribution of component' analysis. This makes it impossible to determine if the benefit comes from the neoadjuvant phase, the adjuvant phase, or both, thus complicating interpretation and clinical application.

John Chatzko said the fourth adjuvant sample was not readily interpretable because of patient attrition, possible test failures, and schedule differences: EV+Pembro was drawn at adjuvant cycle eight day one, gem/cis at surveillance. Tom warned that aspirational serial-testing designs will lose patients, as even INVIGOR-11 struggled to retain them.

An overall survival (OS) benefit in an adjuvant trial may not be meaningful for patients in systems (e.g., the U.S.) with guaranteed access to the same effective immunotherapy upon recurrence. The crucial, unanswered question is whether treating micrometastatic disease is inherently superior to treating macroscopic disease later, a distinction current trial data doesn't clarify.

A significant criticism of the pivotal KEYNOTE-564 trial is that only half the patients in the control arm received standard-of-care immunotherapy upon relapse. This lack of subsequent optimal treatment complicates the interpretation of the overall survival benefit, raising questions about its true magnitude.

The failure of the Checkmate 914 adjuvant trial, which used a six-month duration of nivolumab plus ipilimumab, suggests this shorter treatment window may be inadequate. In contrast to positive trials with one year of therapy, this outcome indicates that treatment duration is a critical variable for achieving a disease-free survival benefit in the adjuvant RCC setting.

While KEYNOTE-905 showed dramatic survival benefits with neoadjuvant plus adjuvant EV-pembrolizumab, its design makes it impossible to isolate the benefit of each phase. The high (57%) pathologic complete response after neoadjuvant therapy alone suggests many patients may be overtreated with adjuvant cycles, risking unnecessary long-term toxicity like neuropathy.

While the pivotal EV-302 trial allowed for indefinite Enfortumab Vedotin (EV) treatment, real-world clinical experience shows very few patients reach the two-year mark due to cumulative toxicity. This highlights a major divergence between clinical trial design and practical application, with only about 10% making it that long.

In clinical practice and clinical trial arms planned for nine perioperative cycles of EV-pembrolizumab, most patients fail to complete therapy due to adverse events. Consequently, real-world clinicians already administer de-escalated regimens resembling shorter three-cycle protocols out of necessity.